Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC

Author's Avatar
Jul 26, 2021

- Phase 1b study of BIIB080/IONIS-MAPT Rx met primary objective of safety and tolerability

- Study demonstrated durable, robust, time and dose dependent lowering of tau protein in cerebrospinal fluid

PR Newswire